Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA hearings in House could begin by last week of February; Bliley promises FDA reform.

This article was originally published in The Tan Sheet

Executive Summary

FDA HOUSE HEARINGS COULD BEGIN AS EARLY AS LAST WEEK IN FEBRUARY in the House Commerce/oversight subcommittee, full committee Chairman Rep. Thomas Bliley (R-Va.) said during an address to the National Committee for Quality Health Care Feb. 1 in Washington, D.C. Bliley vowed: "I promise you, this session in the Commerce Committee there will -- repeat, there will -- be reforms in the way FDA does business." The Senate Labor & Human Resources Committee is expecting to hold hearings on FDA by July ("The Tan Sheet" Jan. 30, In Brief).

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS083709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel